Trial Profile
Phase II Trial of Neoadjuvant Erlotinib Plus Chemotherapy for Treatment of ER Negative, PgR Negative and HER-2 Negative Primary Breast Cancer.
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary) ; Carboplatin; Docetaxel
- Indications Adenocarcinoma; Breast cancer; Triple negative breast cancer
- Focus Biomarker; Therapeutic Use
- 18 Jan 2017 Planned End Date changed from 1 Dec 2015 to 1 Dec 2017.
- 31 Mar 2015 Planned End Date changed from 1 Mar 2015 to 1 Dec 2015, as reported by ClinicalTrials.gov.
- 05 Nov 2014 According to NCT record, planned End Date changed from 1 Dec 2014 to 1 Mar 2015.